CAT vs PFE: Which Is the Better Buy?

Side-by-side comparison of Caterpillar Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Caterpillar Inc. · Industrials
$792.65
-8.8% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric CAT PFE
Current Price $792.65 $26.91
Fair Value Estimate $723.13 $35.00
Upside to Fair Value -8.8% +30.1%
Market Cap $370.9B $153.0B
Forward P/E 41.7x 9.5x
EV / EBITDA 27.2x 13.8x
Price / Sales 5.5x 2.4x
Price / FCF 36.1x 16.8x
Revenue Growth YoY +8.5% -1.6%
Gross Margin 32.3% 70.3%
Operating Margin 16.6% 24.7%
Return on Equity 45.1% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 2.77% 5.9%
Analyst Consensus Buy Hold
Investment Thesis
CAT — Caterpillar Inc.
Caterpillar Inc. is the world's leading manufacturer of construction and mining equipment, engines, and industrial machinery, with a strong global footprint and a record $67.6 billion in revenues for 2025. The company benefits from a durable competitive position supported by a broad product portfolio and a large installed base, but faces margin pressure from tariffs and cost inflation. Despite so…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric CAT PFE
Zone Low $542.35 $25.00
Zone High $614.66 $29.00
In Buy Zone? No Yes
← CAT Research    PFE Research →    All Research